MARÍA PILAR
ESCRIBANO SUBÍAS
Profesora asociada de Ciencias de la Salud
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Marqués de Valdecilla (21)
2024
-
Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot study
Frontiers in Public Health, Vol. 12
-
Risk Stratification in Pulmonary Veno-Occlusive Disease
Archivos de Bronconeumologia
-
Simplified risk stratification based on cardiopulmonary exercise test: A Spanish two-center experience
Pulmonary Circulation, Vol. 14, Núm. 1
2023
-
Usefulness of genetics for clinical reclassification and refinement of prognostic stratification in pulmonary arterial hypertension
Revista Espanola de Cardiologia, Vol. 76, Núm. 6, pp. 460-467
2022
-
Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)
Scientific Reports
-
Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry
Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 260-266
-
Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol
Frontiers in Public Health, Vol. 10
-
Global Emergence of Resistance to Fluconazole and Voriconazole in Candida parapsilosis in Tertiary Hospitals in Spain During the COVID-19 Pandemic
Open Forum Infectious Diseases, Vol. 9, Núm. 11
-
Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
Scientific reports, Vol. 12, Núm. 1, pp. 5289
-
Phenotypes of idiopathic pulmonary arterial hypertension
The Lancet Respiratory Medicine
2021
-
Azole and amphotericin B MIC values against aspergillus fumigatus: High agreement between spectrophotometric and visual readings using the EUCAST EDef 9.3.2 procedure
Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 1
-
Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain
Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1170.e1-1170.e7
-
Chronic thromboembolic pulmonary hypertension in Spain: a decade of change
Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 384-392
-
From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?
Advances in Therapy, Vol. 38, Núm. 4, pp. 1860-1875
-
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Respiratory Medicine, Vol. 178
2020
-
Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4
PLoS ONE, Vol. 15, Núm. 4
2019
-
Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry
International Journal of Cardiology, Vol. 275, pp. 158-164
2018
-
Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival
Revista Espanola de Cardiologia, Vol. 71, Núm. 2, pp. 117-118
2014
-
Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?
International Journal of Cardiology, Vol. 171, Núm. 1, pp. 15-23
2013
-
Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation
Clinical Transplantation, Vol. 27, Núm. 6